Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial
Abstract
Renin-angiotensin-aldosterone inhibitors (RAASi) improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF), but their use is often limited by hyperkalaemia in chronic kidney disease (CKD) patients. This double-blind, placebo-controlled, randomised trial evaluated whether sodium zirconium cyclosilicate (SZC) enables RAASi up-titration in HFrEF patients with CKD stages 3–5 and serum potassium of 5.0–5.5 mmol/L over 14 weeks. The primary binary outcome was defined as achieving the target dose of RAAS inhibition therapy without reaching hyperkalaemia (serum potassium ≥5.6 mmol/L) over 14 weeks or otherwise. Participants ( n = 112) were randomised 1:1 to receive sodium zirconium cyclosilicate (SZC) or placebo. The per-protocol (PP) analyses included 43 out of 53 (81%) in the SZC arm and 53 out of 59 participants (90%) in the placebo arm; the intention-to-treat (ITT) analyses included all 112. At the end of the trial, 24 of 43 participants (56%) in the SZC group achieved the target RAASi dose without developing hyperkalaemia compared with 15 of 53 patients (28%) in the placebo group (PP analysis, p = 0.006, ITT analysis, p = 0.007,). Participants in the SZC group were 3 times more likely to reach the target dose without reaching potassium 5.6 mmol/L (OR = 3.16; 95% CI 1.35–7.39; p = 0.008) than in the placebo group (ITT analysis). No significant differences in adverse events between the two groups were observed. SZC appears to safely support rapid RAASi optimisation in HFrEF patients with CKD. This trial was funded by AstraZeneca via Externally Sponsored Scientific Research grant ESR-19-20174. Trial Registration: Clinicaltrials.gov NCT05004363 and EudraCT number 2020-002946-18.
Related
- OCT-guided versus angiography-guided stent optimisation for post-interventional FFR in patients with complex coronary artery lesions: protocol for a multicentre, open-label, randomised controlled trial (PRECISION-COMPLEX)
- The AGT M235T variant and renin-angiotensin-aldosterone system parameters in a predominantly hypertensive elderly black South African cohort: a hypothesis-generating descriptive case series.
- Angiotensin receptor neprilysin inhibitor (ARNI) in right ventricular failure and preserved LV ejection fraction: A systematic review and meta-analysis.
- Renin-Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study.
- Cardiac Reverse Remodeling and Clinical Outcomes Following Angiotensin Receptor‐Neprilysin Inhibitor Therapy in Heart Failure With Reduced Ejection Fraction
BibTeX
@article{banerjee2026rapid,
title = {{Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial}},
author = {Debasish Banerjee and Mahrukh Ali and Ella Tumelty and Daniel Murphy and Hilary Warrens and Simran Parmar and Thomas McNally and Tony Lopez and Sharirose Abat and Riny Paul and Sabba Hussain and Souradip Mookerjee and Isaac Chung and Irina Chis Ster and Lisa Anderson},
journal = {Nature Communications},
year = {2026},
month = oct,
doi = {10.1038/s41467-026-78377-0},
url = {https://www.nature.com/articles/s41467-026-78377-0},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial
AU - Debasish Banerjee
AU - Mahrukh Ali
AU - Ella Tumelty
AU - Daniel Murphy
AU - Hilary Warrens
AU - Simran Parmar
AU - Thomas McNally
AU - Tony Lopez
AU - Sharirose Abat
AU - Riny Paul
AU - Sabba Hussain
AU - Souradip Mookerjee
AU - Isaac Chung
AU - Irina Chis Ster
AU - Lisa Anderson
PY - 2026
DA - 2026/10/14
JO - Nature Communications
DO - 10.1038/s41467-026-78377-0
UR - https://www.nature.com/articles/s41467-026-78377-0
AB - Renin-angiotensin-aldosterone inhibitors (RAASi) improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF), but their use is often limited by hyperkalaemia in chronic kidney disease (CKD) patients. This double-blind, placebo-controlled, randomised trial evaluated whether sodium zirconium cyclosilicate (SZC) enables RAASi up-titration in HFrEF patients with CKD stages 3–5 and serum potassium of 5.0–5.5 mmol/L over 14 weeks. The primary binary outcome was defined as achieving the target dose of RAAS inhibition therapy without reaching hyperkalaemia (serum potassium ≥5.6 mmol/L) over 14 weeks or otherwise. Participants ( n = 112) were randomised 1:1 to receive sodium zirconium cyclosilicate (SZC) or placebo. The per-protocol (PP) analyses included 43 out of 53 (81%) in the SZC arm and 53 out of 59 participants (90%) in the placebo arm; the intention-to-treat (ITT) analyses included all 112. At the end of the trial, 24 of 43 participants (56%) in the SZC group achieved the target RAASi dose without developing hyperkalaemia compared with 15 of 53 patients (28%) in the placebo group (PP analysis, p = 0.006, ITT analysis, p = 0.007,). Participants in the SZC group were 3 times more likely to reach the target dose without reaching potassium 5.6 mmol/L (OR = 3.16; 95% CI 1.35–7.39; p = 0.008) than in the placebo group (ITT analysis). No significant differences in adverse events between the two groups were observed. SZC appears to safely support rapid RAASi optimisation in HFrEF patients with CKD. This trial was funded by AstraZeneca via Externally Sponsored Scientific Research grant ESR-19-20174. Trial Registration: Clinicaltrials.gov NCT05004363 and EudraCT number 2020-002946-18.
SN - 2041-1723
ER -